- Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
- Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
- Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Denali Therapeutics Announces $500 million Private Placement Equity Financing
- Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
- Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
- Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
- Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
- Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
- Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
More ▼
Key statistics
As of last trade, Denali Therapeutics Inc (DNLI:NSQ) traded at 19.26, 32.28% above the 52 week low of 14.56 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.11 |
---|---|
High | 20.11 |
Low | 18.89 |
Bid | 17.50 |
Offer | 21.60 |
Previous close | 19.26 |
Average volume | 887.96k |
---|---|
Shares outstanding | 142.61m |
Free float | 123.10m |
P/E (TTM) | -- |
Market cap | 2.75bn USD |
EPS (TTM) | -0.9661 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼